fragment of the p80 region (nucleotides 5801-67 18) were cloned into the 3' end of the GST gene. The pGex3X-gp48 expression vector directed a 39-kD protein, which is the sum of the GST (26 kD) and gp48 (13 kD) sequences inserted into the expression vector. The pGex2T-p80 expression vector directed a 58-kD protein, which is the sum of the GST (26 kD) and p80 (32 kD) sequences inserted into the expression vector. The gp25 fragment was generated by a polymerase chain reaction using pBV4-gp62 as a template. To select an appropriate gene fragment for expression, gp25 gene sequences were translated through GENBANK by the IBI Pustell Sequence Analysis Program. 7, 10 Amino acids 607-634 of BVDV-NADL (which correspond to nucleotides 2204-2287) probably possess an immunodominant epitope, as indicated by calculating the antigenic index, hydrophilicity, flexibility, surface probability, and secondary structure (data not shown). Therefore, 2 primers (5'-TTGGATCCGTAA-TACCAGGGTCG, 5'-TCGAATTCCAACACTACAGT-TGT) carrying the BamHI and EcoRI linkers were used to amplify 84 bp of the gp25 region (nucleotides 2204-2287). The primers and amplified product were designed to be in frame with GST of the pGex2T expression vector. The final plasmid pGex2T-gp25 was introduced into JM105 bacterial cells and induced by isopropyl-D-thiogalactopyranoside. 9 The expression and antigenicity of the gp25 fusion protein with the gp48 and p80 recombinant proteins are shown in Fig. 1 . The gp48, gp25, and p80 recombinant proteins were enriched by sequential extraction with 1, 6, and 8 M urea buffers and sodium dodecyl sulfate (SDS) buffer. The enriched fractions were then subjected to SDS-polyacrylamide gel electrophoresis (PAGE). Each recombinant protein band was excised and eluted from the gel slice. All of the reagents (including the amount of purified protein to coat plates, optimal serum sample dilutions, and secondary antibody dilution, which were used to develop an immunoassay for BVDV serology) were determined using checkerboard titrations. The recombinant proteins were dissolved individually in 0.01 M NaHCO 3 buffer (pH 9.6) and used to coat 96-well microtiter plates b (100 ng/well). The plates were dried by evaporation overnight at 37 C. Each recombinant protein was tested for reactivity against a panel of cattle sera. The cutoff value was set to 4 SD above the net absorbance of negative-reference sera to minimize the potential for false-positive results. The net absorbance was defined as the sample absorbance minus the negative-control absorbance for each plate. Thus, the cutoff values for gp48, gp25, and p80 ELISAs were 0.180, 0.210, and 0.180 optical density units, respectively.
A panel of 100 sera were included in this study. For group A, 91 samples were collected from animals naturally or experimentally infected with BVDV or from vaccinated (modified live or killed virus) animals, which were scored serologically positive by VN test (VN titer: 1:2-1:4,096). In group B, 3 serum samples were used as the negative reference. These animals had never been infected with BVDV. In group C, 6 Serum samples were collected from 2 herds in which BVD had been diagnosed. The VN titer of group C sera was negative (<1:2) for an antibody against BVDV.
When group A serum samples were screened at the optimal dilution (1:75), gp48, gp25, and p80 recombinant proteins reacted to 91/91 (100%), 90/91 (98.9%), and 84/91 (92.3%) sera in each recombinant ELISA, respectively. In contrast, none of the group B negative-reference sera or group C sera reacted with any of the 3 proteins (Table 1) . Thus, the group C sera were likely from uninfected animals. These results indicated that gp48 was the most effective protein to use in detecting infected animals. When results of the recombinant gp48 used in western blot assay were compared with those of the VN test, gp48 was sensitive and specific for detection of antibody against BVDV. 9 Serum samples were collected from 7 cattle after they had received the first of 2 killed-virus vaccinations. These samples tested negative using p80 proteins and positive using gp48, gp25, and VN tests (1:2-1:8). Results of radioimmunoprecipitation of BVDV-induced proteins using these 7 sera completely agreed with these ELISA and VN results. 8 However, after cattle received a second dose of killed BVD vac-tine, antibodies to all 3 proteins were detected. These sera had higher neutralization activity (≥1:16) than did sera from cattle vaccinated only once. The recombinant gp48 and gp25 proteins were readily recognized by sera that had low or high titers of VN antibody. The killed vaccine used in this study had not been centrifuged to remove cell debris before the virus was killed. The methods used to prepare BVDV killed vaccine may affect the ability of the vaccine to elicit p80 immune response in cattle. 2 Differences in vaccine prepa- rations (such as the presence of cell debris or differences in virus inactivating reagents, etc.) and the number of injections received can affect the p80 immune response.
The significance of this finding is 2-fold. First, a test for antibody against p80 differentiated among sera obtained from cattle vaccinated with killed-virus vaccine, vaccinated with modified live-virus vaccine, or naturally infected. Second, cattle produced antibodies against gp48 and gp25 following exposure either to BVDV (natural or experimental infection) or to vaccines (killed and modified live). Because these antibodies were readily recognized by recombinant gp48 and gp25, this finding might imply that some of the epitopes on gp48 or gp25 are highly conserved among BVDV strains.
The application of recombinant proteins for BVDV serology were significant in 2 respects. First, use of recombinant proteins eliminated the need for conventional tissue culture methods to run a VN assay or to produce viral antigens for a whole-virus ELISA. Although the initial development of recombinant BVDV proteins was a biotechnology-intensive and time-consuming process, it represented a one-time investment of resources and efforts. After that, it was possible to produce and purify sufficient recombinant antigens in 2 days to test several thousand sera. In contrast, VN or wholevirus ELISA testing require long-term tissue culture of bovine cells and centrifugation process. In addition, the growth and technical requirements for bacterial culture of Escherichia coli to produce recombinant proteins are simpler and less expensive than those of assays depending on tissue cultures. Second, in comparison with the whole-virus ELISA, the quantity and the purity levels of the recombinant protein decreases false-positive reaction caused by the presence of the cellular antigens in the viral antigen preparation. Thus, increased specificity, sensitivity, and reproducibility of the test are achieved. In conclusion, the use of BVDV gp48 or gp25 recombinant protein in an ELISA could be an effective tool for diagnosis and control of BVD in large and small cattle herds.
